BR112022016359A2 - Formas cristalinas de um composto farmacêutico - Google Patents

Formas cristalinas de um composto farmacêutico

Info

Publication number
BR112022016359A2
BR112022016359A2 BR112022016359A BR112022016359A BR112022016359A2 BR 112022016359 A2 BR112022016359 A2 BR 112022016359A2 BR 112022016359 A BR112022016359 A BR 112022016359A BR 112022016359 A BR112022016359 A BR 112022016359A BR 112022016359 A2 BR112022016359 A2 BR 112022016359A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
pharmaceutical compound
compound
pharmaceutical
forms
Prior art date
Application number
BR112022016359A
Other languages
English (en)
Inventor
Charles Reader John
Conor Marshall Jamie
Mykytiuk John
Scott Northen Julian
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of BR112022016359A2 publication Critical patent/BR112022016359A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

FORMAS CRISTALINAS DE UM COMPOSTO FARMACÊUTICO. A invenção provê formas cristalinas de um composto tendo a fórmula (1), juntamente com métodos para fazer as formas cristalinas e formulações farmacêuticas compreendendo as formas cristalinas.
BR112022016359A 2020-04-07 2021-04-06 Formas cristalinas de um composto farmacêutico BR112022016359A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound
PCT/EP2021/058864 WO2021204762A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor

Publications (1)

Publication Number Publication Date
BR112022016359A2 true BR112022016359A2 (pt) 2022-10-04

Family

ID=70768933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016359A BR112022016359A2 (pt) 2020-04-07 2021-04-06 Formas cristalinas de um composto farmacêutico

Country Status (12)

Country Link
US (1) US20230159473A1 (pt)
EP (1) EP4132649A1 (pt)
JP (1) JP2023521631A (pt)
KR (1) KR20220164751A (pt)
CN (1) CN115515683A (pt)
AU (1) AU2021253128A1 (pt)
BR (1) BR112022016359A2 (pt)
CA (1) CA3167172A1 (pt)
GB (1) GB202005114D0 (pt)
IL (1) IL296989A (pt)
MX (1) MX2022011593A (pt)
WO (1) WO2021204762A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183910A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Solid forms of tyk2 inhibitors and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
WO2008156726A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Inhibitors of janus kinases
JP2011518221A (ja) 2008-04-21 2011-06-23 メルク・シャープ・エンド・ドーム・コーポレイション Ｊａｎｕｓキナーゼの阻害剤
CA2727928A1 (en) 2008-06-18 2009-12-23 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CN102869359A (zh) 2010-03-17 2013-01-09 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶和嘌呤化合物、组合物和使用方法
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
DK3040336T3 (da) 2012-03-02 2020-06-22 Sareum Ltd Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
PT3495358T (pt) 2012-11-08 2022-06-02 Bristol Myers Squibb Co Compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifn-alfa
BR112016004723B1 (pt) 2013-09-03 2022-08-30 Sareum Limited Compostos de pirrolidina ou morfolina e composição contendo os mesmos
NO2721710T3 (pt) 2014-08-21 2018-03-31
GB201617871D0 (en) * 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB201816369D0 (en) * 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
IL296989A (en) 2022-12-01
CA3167172A1 (en) 2021-10-14
GB202005114D0 (en) 2020-05-20
US20230159473A1 (en) 2023-05-25
EP4132649A1 (en) 2023-02-15
WO2021204762A1 (en) 2021-10-14
CN115515683A (zh) 2022-12-23
JP2023521631A (ja) 2023-05-25
MX2022011593A (es) 2022-10-18
KR20220164751A (ko) 2022-12-13
AU2021253128A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
WO2020243415A3 (en) Tead inhibitors and uses thereof
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
CR20210247A (es) Nuevos compuestos heterocíclicos
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
DOP2020000023A (es) Nuevos derivados de quinolina
CL2020002056A1 (es) Formas cristalinas novedosas.
UY38716A (es) Derivados de isoxazolina herbicidamente activos, y procesos e intermediarios utilizados para la preparación de estos derivados
CR20200116A (es) Compuestos de bisamida que activan el sarcómero y sus usos
CO2020013876A2 (es) Nuevos derivados de quinolina
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CR20220251A (es) Nuevos derivados de metilquinazolinona
CO2023013469A2 (es) Derivados de fósforo como nuevos inhibidores de sos1
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
BR112023003106A2 (pt) Forma amorfa de um inibidor de malt1 e formulações do mesmo
BR112022016359A2 (pt) Formas cristalinas de um composto farmacêutico
AR114270A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmacéutico
CU20190095A7 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
BR112023019435A2 (pt) Inibidores de nek7
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
CL2021001826A1 (es) Formas cristalinas de 1-(1,2-dimetilpropil)-n-etil-5-metil-n-piridazin-4-il-pirazol-4-carboxamida
BR112022009809A2 (pt) Agentes de formação de imagem de pré-alvejamento
BR112022017133A2 (pt) Composições compreendendo pró-drogas de metilfenidato, processos de fabricação e uso das mesmas
ECSP22046595A (es) Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina